Enhancement of hyperthermic toxicity by lonidarnine in the dunning R3327G rat prostatic adenocarcinoma

William E. Bloch, Balakrishna L Lokeshwar, Sean M. Ferrell, Norman L. Block

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hyperthermia alone or with radiation is used therapeutically for localized solid tumors. Clinical experience shows that sustained tumor temperature exceeding 45°C damages normal tissue. Any agent that enhances the effects of hyperthermia at or below this temperature may have clinical relevance. Lonidamine and hyperthermia were tested on the Dunning R3327G rat prostatic adenocarcinoma. Using colony‐formation assays, cytotoxic effects of each agent alone and in combination were quantified. Lonidamine to 100 μg/ml was not significantly toxic, but in combination, it enhanced cytotoxicity. Survival patterns after fractionated hyperthermia revealed a rapid development and decay of thermotolerance. Measurement of cell‐cycle progression following a single dose of hyperthermia revealed a reduction of S‐phase cells, and subsequent accumulation in G1 over 24 hours. Combination treatment of tumor‐bearing rats significantly reduced tumor growth rate when compared with individual agents. These results suggest a potential use of lonidamine in hyperthermic therapy of prostate tumors. © 1994 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalThe Prostate
Volume24
Issue number3
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Adenocarcinoma
Fever
Neoplasms
Temperature
Poisons
Prostate
Radiation
Growth
lonidamine
Therapeutics

Keywords

  • hyperthermia
  • lonidamine
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Enhancement of hyperthermic toxicity by lonidarnine in the dunning R3327G rat prostatic adenocarcinoma. / Bloch, William E.; Lokeshwar, Balakrishna L; Ferrell, Sean M.; Block, Norman L.

In: The Prostate, Vol. 24, No. 3, 01.01.1994, p. 131-138.

Research output: Contribution to journalArticle

Bloch, William E. ; Lokeshwar, Balakrishna L ; Ferrell, Sean M. ; Block, Norman L. / Enhancement of hyperthermic toxicity by lonidarnine in the dunning R3327G rat prostatic adenocarcinoma. In: The Prostate. 1994 ; Vol. 24, No. 3. pp. 131-138.
@article{ba69c9b615934b708189aa35bea8b226,
title = "Enhancement of hyperthermic toxicity by lonidarnine in the dunning R3327G rat prostatic adenocarcinoma",
abstract = "Hyperthermia alone or with radiation is used therapeutically for localized solid tumors. Clinical experience shows that sustained tumor temperature exceeding 45°C damages normal tissue. Any agent that enhances the effects of hyperthermia at or below this temperature may have clinical relevance. Lonidamine and hyperthermia were tested on the Dunning R3327G rat prostatic adenocarcinoma. Using colony‐formation assays, cytotoxic effects of each agent alone and in combination were quantified. Lonidamine to 100 μg/ml was not significantly toxic, but in combination, it enhanced cytotoxicity. Survival patterns after fractionated hyperthermia revealed a rapid development and decay of thermotolerance. Measurement of cell‐cycle progression following a single dose of hyperthermia revealed a reduction of S‐phase cells, and subsequent accumulation in G1 over 24 hours. Combination treatment of tumor‐bearing rats significantly reduced tumor growth rate when compared with individual agents. These results suggest a potential use of lonidamine in hyperthermic therapy of prostate tumors. {\circledC} 1994 Wiley‐Liss, Inc.",
keywords = "hyperthermia, lonidamine, prostate cancer",
author = "Bloch, {William E.} and Lokeshwar, {Balakrishna L} and Ferrell, {Sean M.} and Block, {Norman L.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/pros.2990240306",
language = "English (US)",
volume = "24",
pages = "131--138",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Enhancement of hyperthermic toxicity by lonidarnine in the dunning R3327G rat prostatic adenocarcinoma

AU - Bloch, William E.

AU - Lokeshwar, Balakrishna L

AU - Ferrell, Sean M.

AU - Block, Norman L.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Hyperthermia alone or with radiation is used therapeutically for localized solid tumors. Clinical experience shows that sustained tumor temperature exceeding 45°C damages normal tissue. Any agent that enhances the effects of hyperthermia at or below this temperature may have clinical relevance. Lonidamine and hyperthermia were tested on the Dunning R3327G rat prostatic adenocarcinoma. Using colony‐formation assays, cytotoxic effects of each agent alone and in combination were quantified. Lonidamine to 100 μg/ml was not significantly toxic, but in combination, it enhanced cytotoxicity. Survival patterns after fractionated hyperthermia revealed a rapid development and decay of thermotolerance. Measurement of cell‐cycle progression following a single dose of hyperthermia revealed a reduction of S‐phase cells, and subsequent accumulation in G1 over 24 hours. Combination treatment of tumor‐bearing rats significantly reduced tumor growth rate when compared with individual agents. These results suggest a potential use of lonidamine in hyperthermic therapy of prostate tumors. © 1994 Wiley‐Liss, Inc.

AB - Hyperthermia alone or with radiation is used therapeutically for localized solid tumors. Clinical experience shows that sustained tumor temperature exceeding 45°C damages normal tissue. Any agent that enhances the effects of hyperthermia at or below this temperature may have clinical relevance. Lonidamine and hyperthermia were tested on the Dunning R3327G rat prostatic adenocarcinoma. Using colony‐formation assays, cytotoxic effects of each agent alone and in combination were quantified. Lonidamine to 100 μg/ml was not significantly toxic, but in combination, it enhanced cytotoxicity. Survival patterns after fractionated hyperthermia revealed a rapid development and decay of thermotolerance. Measurement of cell‐cycle progression following a single dose of hyperthermia revealed a reduction of S‐phase cells, and subsequent accumulation in G1 over 24 hours. Combination treatment of tumor‐bearing rats significantly reduced tumor growth rate when compared with individual agents. These results suggest a potential use of lonidamine in hyperthermic therapy of prostate tumors. © 1994 Wiley‐Liss, Inc.

KW - hyperthermia

KW - lonidamine

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0028348527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028348527&partnerID=8YFLogxK

U2 - 10.1002/pros.2990240306

DO - 10.1002/pros.2990240306

M3 - Article

VL - 24

SP - 131

EP - 138

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -